Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo

Carlo Dell'Erba, Barbara Chiavarina, Carla Fenoglio, Giovanni Petrillo, Cinzia Cordazzo, Eleonora Boncompagni, Domenico Spinelli, Emanuela Ognio, Cinzia Aiello, Maria A. Mariggiò, Maurizio Viale

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Our preliminary data suggested that 1,4-bis(1-naphthyl)-2,3-dinitro-1,3- butadiene [Viale M, Ottone M, Chiavarina B, Mariggiò MA, Prevosto C, Dell'Erba C, et al. Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2, 3-dinitro-1,3-butadiene. Invest New Drug 2004;22:359-67] (Naph-DNB), possesses good characteristics in terms of inhibition of cell proliferation in two cell lines derived from colon and gastric cancers. On this basis and to confirm the specificity of our compound towards gastrointestinal malignancies, we have analyzed the inhibition of cell proliferation, the cytotoxicity and the induction of apoptosis by Naph-DNB in seven cell lines derived from human colon (DLD-1, Lovo, HCT-8 and Colo 741), stomach (HGC-27) and pancreas (Panc-1 and Hup-T4) tumours. For the sake of comparison, cells have also been exposed to four anticancer drugs utilized for the treatment of gastrointestinal malignancies (oxaliplatin, irinotecan, gemcitabine and 5-fluorouracil). Moreover, toxicological data have been obtained in order to define the lethal dose (LD) and maximal tolerated dose (MTD) values and the spectrum of tissue alterations caused by the intraperitoneal (i.p.) and intravenous (i.v.) administration of Naph-DNB. IC50 data obtained by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay suggest that Naph-DNB is generally more active than two or more of the anticancer drugs above in most cell lines: it displayed the lowest activity only in HGC-27 cells, although data concerning the IC75 parameter enlighten a significantly better activity than irinotecan and 5-fluorouracil. Using the equitoxic concentrations IC50 and IC75, we have also evaluated the ability of Naph-DNB and of the other anticancer drugs to kill cells and to induce apoptosis. Our data show that at these concentrations Naph-DNB has a cytotoxic activity comparable or even better than that of some anticancer drugs. Similarly, Naph-DNB induces apoptosis better than the other anticancer drugs in HCT-8 and HGC-27 cells, while in Lovo and Panc-1 cells the induction is comparable. On the basis of toxicological data we defined the LD10, LD50, LD90 (i.p., 17.6, 36.1 and 54.1 mg kg-1, respectively; i.v., 6.1, 14.1 and 22.0 mg kg-1, respectively) and the MTD (i.p., 15 mg kg-1; i.v., 5 mg kg -1) parameters. Histochemical analysis has shown that, in general, the administration of even toxic doses of Naph-DNB does not cause great structural injuries, although it can have some effects on the metabolism of glicogen and iron in organs as liver and spleen. In conclusion, our preclinical studies in vitro suggest that Naph-DNB may represent a good anticancer compound for the treatment of generally unresponsive tumours such as those of pancreas, stomach and colon. Moreover, the analysis of its toxic effects has allowed the definition of LD and MTD parameters, which will be used in further experiments in vivo for the definition of its antitumour activity.

Original languageEnglish
Pages (from-to)271-282
Number of pages12
JournalPharmacological Research
Volume52
Issue number3
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Tumor Cell Line
irinotecan
Cell Proliferation
Apoptosis
Maximum Tolerated Dose
Pharmaceutical Preparations
oxaliplatin
Poisons
gemcitabine
Cell Line
Fluorouracil
Toxicology
Inhibitory Concentration 50
Pancreas
Neoplasms
Stomach
Colon
Lethal Dose 50
Intravenous Administration
Colonic Neoplasms

Keywords

  • 1,4-bis(1-Naphthyl)-2,3-dinitro-1,3-butadiene
  • Apoptosis
  • Gastrointestinal tumour cell lines
  • Growth inhibition
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology

Cite this

Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo. / Dell'Erba, Carlo; Chiavarina, Barbara; Fenoglio, Carla; Petrillo, Giovanni; Cordazzo, Cinzia; Boncompagni, Eleonora; Spinelli, Domenico; Ognio, Emanuela; Aiello, Cinzia; Mariggiò, Maria A.; Viale, Maurizio.

In: Pharmacological Research, Vol. 52, No. 3, 09.2005, p. 271-282.

Research output: Contribution to journalArticle

Dell'Erba, Carlo ; Chiavarina, Barbara ; Fenoglio, Carla ; Petrillo, Giovanni ; Cordazzo, Cinzia ; Boncompagni, Eleonora ; Spinelli, Domenico ; Ognio, Emanuela ; Aiello, Cinzia ; Mariggiò, Maria A. ; Viale, Maurizio. / Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo. In: Pharmacological Research. 2005 ; Vol. 52, No. 3. pp. 271-282.
@article{7eda2685f45f428abf0cc09c02062ef5,
title = "Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo",
abstract = "Our preliminary data suggested that 1,4-bis(1-naphthyl)-2,3-dinitro-1,3- butadiene [Viale M, Ottone M, Chiavarina B, Mariggi{\`o} MA, Prevosto C, Dell'Erba C, et al. Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2, 3-dinitro-1,3-butadiene. Invest New Drug 2004;22:359-67] (Naph-DNB), possesses good characteristics in terms of inhibition of cell proliferation in two cell lines derived from colon and gastric cancers. On this basis and to confirm the specificity of our compound towards gastrointestinal malignancies, we have analyzed the inhibition of cell proliferation, the cytotoxicity and the induction of apoptosis by Naph-DNB in seven cell lines derived from human colon (DLD-1, Lovo, HCT-8 and Colo 741), stomach (HGC-27) and pancreas (Panc-1 and Hup-T4) tumours. For the sake of comparison, cells have also been exposed to four anticancer drugs utilized for the treatment of gastrointestinal malignancies (oxaliplatin, irinotecan, gemcitabine and 5-fluorouracil). Moreover, toxicological data have been obtained in order to define the lethal dose (LD) and maximal tolerated dose (MTD) values and the spectrum of tissue alterations caused by the intraperitoneal (i.p.) and intravenous (i.v.) administration of Naph-DNB. IC50 data obtained by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay suggest that Naph-DNB is generally more active than two or more of the anticancer drugs above in most cell lines: it displayed the lowest activity only in HGC-27 cells, although data concerning the IC75 parameter enlighten a significantly better activity than irinotecan and 5-fluorouracil. Using the equitoxic concentrations IC50 and IC75, we have also evaluated the ability of Naph-DNB and of the other anticancer drugs to kill cells and to induce apoptosis. Our data show that at these concentrations Naph-DNB has a cytotoxic activity comparable or even better than that of some anticancer drugs. Similarly, Naph-DNB induces apoptosis better than the other anticancer drugs in HCT-8 and HGC-27 cells, while in Lovo and Panc-1 cells the induction is comparable. On the basis of toxicological data we defined the LD10, LD50, LD90 (i.p., 17.6, 36.1 and 54.1 mg kg-1, respectively; i.v., 6.1, 14.1 and 22.0 mg kg-1, respectively) and the MTD (i.p., 15 mg kg-1; i.v., 5 mg kg -1) parameters. Histochemical analysis has shown that, in general, the administration of even toxic doses of Naph-DNB does not cause great structural injuries, although it can have some effects on the metabolism of glicogen and iron in organs as liver and spleen. In conclusion, our preclinical studies in vitro suggest that Naph-DNB may represent a good anticancer compound for the treatment of generally unresponsive tumours such as those of pancreas, stomach and colon. Moreover, the analysis of its toxic effects has allowed the definition of LD and MTD parameters, which will be used in further experiments in vivo for the definition of its antitumour activity.",
keywords = "1,4-bis(1-Naphthyl)-2,3-dinitro-1,3-butadiene, Apoptosis, Gastrointestinal tumour cell lines, Growth inhibition, Toxicity",
author = "Carlo Dell'Erba and Barbara Chiavarina and Carla Fenoglio and Giovanni Petrillo and Cinzia Cordazzo and Eleonora Boncompagni and Domenico Spinelli and Emanuela Ognio and Cinzia Aiello and Mariggi{\`o}, {Maria A.} and Maurizio Viale",
year = "2005",
month = "9",
doi = "10.1016/j.phrs.2005.03.011",
language = "English",
volume = "52",
pages = "271--282",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",
number = "3",

}

TY - JOUR

T1 - Inhibition of cell proliferation, cytotoxicity and induction of apoptosis of 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene in gastrointestinal tumour cell lines and preliminary evaluation of its toxicity in vivo

AU - Dell'Erba, Carlo

AU - Chiavarina, Barbara

AU - Fenoglio, Carla

AU - Petrillo, Giovanni

AU - Cordazzo, Cinzia

AU - Boncompagni, Eleonora

AU - Spinelli, Domenico

AU - Ognio, Emanuela

AU - Aiello, Cinzia

AU - Mariggiò, Maria A.

AU - Viale, Maurizio

PY - 2005/9

Y1 - 2005/9

N2 - Our preliminary data suggested that 1,4-bis(1-naphthyl)-2,3-dinitro-1,3- butadiene [Viale M, Ottone M, Chiavarina B, Mariggiò MA, Prevosto C, Dell'Erba C, et al. Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2, 3-dinitro-1,3-butadiene. Invest New Drug 2004;22:359-67] (Naph-DNB), possesses good characteristics in terms of inhibition of cell proliferation in two cell lines derived from colon and gastric cancers. On this basis and to confirm the specificity of our compound towards gastrointestinal malignancies, we have analyzed the inhibition of cell proliferation, the cytotoxicity and the induction of apoptosis by Naph-DNB in seven cell lines derived from human colon (DLD-1, Lovo, HCT-8 and Colo 741), stomach (HGC-27) and pancreas (Panc-1 and Hup-T4) tumours. For the sake of comparison, cells have also been exposed to four anticancer drugs utilized for the treatment of gastrointestinal malignancies (oxaliplatin, irinotecan, gemcitabine and 5-fluorouracil). Moreover, toxicological data have been obtained in order to define the lethal dose (LD) and maximal tolerated dose (MTD) values and the spectrum of tissue alterations caused by the intraperitoneal (i.p.) and intravenous (i.v.) administration of Naph-DNB. IC50 data obtained by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay suggest that Naph-DNB is generally more active than two or more of the anticancer drugs above in most cell lines: it displayed the lowest activity only in HGC-27 cells, although data concerning the IC75 parameter enlighten a significantly better activity than irinotecan and 5-fluorouracil. Using the equitoxic concentrations IC50 and IC75, we have also evaluated the ability of Naph-DNB and of the other anticancer drugs to kill cells and to induce apoptosis. Our data show that at these concentrations Naph-DNB has a cytotoxic activity comparable or even better than that of some anticancer drugs. Similarly, Naph-DNB induces apoptosis better than the other anticancer drugs in HCT-8 and HGC-27 cells, while in Lovo and Panc-1 cells the induction is comparable. On the basis of toxicological data we defined the LD10, LD50, LD90 (i.p., 17.6, 36.1 and 54.1 mg kg-1, respectively; i.v., 6.1, 14.1 and 22.0 mg kg-1, respectively) and the MTD (i.p., 15 mg kg-1; i.v., 5 mg kg -1) parameters. Histochemical analysis has shown that, in general, the administration of even toxic doses of Naph-DNB does not cause great structural injuries, although it can have some effects on the metabolism of glicogen and iron in organs as liver and spleen. In conclusion, our preclinical studies in vitro suggest that Naph-DNB may represent a good anticancer compound for the treatment of generally unresponsive tumours such as those of pancreas, stomach and colon. Moreover, the analysis of its toxic effects has allowed the definition of LD and MTD parameters, which will be used in further experiments in vivo for the definition of its antitumour activity.

AB - Our preliminary data suggested that 1,4-bis(1-naphthyl)-2,3-dinitro-1,3- butadiene [Viale M, Ottone M, Chiavarina B, Mariggiò MA, Prevosto C, Dell'Erba C, et al. Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2, 3-dinitro-1,3-butadiene. Invest New Drug 2004;22:359-67] (Naph-DNB), possesses good characteristics in terms of inhibition of cell proliferation in two cell lines derived from colon and gastric cancers. On this basis and to confirm the specificity of our compound towards gastrointestinal malignancies, we have analyzed the inhibition of cell proliferation, the cytotoxicity and the induction of apoptosis by Naph-DNB in seven cell lines derived from human colon (DLD-1, Lovo, HCT-8 and Colo 741), stomach (HGC-27) and pancreas (Panc-1 and Hup-T4) tumours. For the sake of comparison, cells have also been exposed to four anticancer drugs utilized for the treatment of gastrointestinal malignancies (oxaliplatin, irinotecan, gemcitabine and 5-fluorouracil). Moreover, toxicological data have been obtained in order to define the lethal dose (LD) and maximal tolerated dose (MTD) values and the spectrum of tissue alterations caused by the intraperitoneal (i.p.) and intravenous (i.v.) administration of Naph-DNB. IC50 data obtained by the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay suggest that Naph-DNB is generally more active than two or more of the anticancer drugs above in most cell lines: it displayed the lowest activity only in HGC-27 cells, although data concerning the IC75 parameter enlighten a significantly better activity than irinotecan and 5-fluorouracil. Using the equitoxic concentrations IC50 and IC75, we have also evaluated the ability of Naph-DNB and of the other anticancer drugs to kill cells and to induce apoptosis. Our data show that at these concentrations Naph-DNB has a cytotoxic activity comparable or even better than that of some anticancer drugs. Similarly, Naph-DNB induces apoptosis better than the other anticancer drugs in HCT-8 and HGC-27 cells, while in Lovo and Panc-1 cells the induction is comparable. On the basis of toxicological data we defined the LD10, LD50, LD90 (i.p., 17.6, 36.1 and 54.1 mg kg-1, respectively; i.v., 6.1, 14.1 and 22.0 mg kg-1, respectively) and the MTD (i.p., 15 mg kg-1; i.v., 5 mg kg -1) parameters. Histochemical analysis has shown that, in general, the administration of even toxic doses of Naph-DNB does not cause great structural injuries, although it can have some effects on the metabolism of glicogen and iron in organs as liver and spleen. In conclusion, our preclinical studies in vitro suggest that Naph-DNB may represent a good anticancer compound for the treatment of generally unresponsive tumours such as those of pancreas, stomach and colon. Moreover, the analysis of its toxic effects has allowed the definition of LD and MTD parameters, which will be used in further experiments in vivo for the definition of its antitumour activity.

KW - 1,4-bis(1-Naphthyl)-2,3-dinitro-1,3-butadiene

KW - Apoptosis

KW - Gastrointestinal tumour cell lines

KW - Growth inhibition

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=22144435875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22144435875&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2005.03.011

DO - 10.1016/j.phrs.2005.03.011

M3 - Article

C2 - 15921920

AN - SCOPUS:22144435875

VL - 52

SP - 271

EP - 282

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 3

ER -